Kenvue's Tylenol Sales Under Fire: Should You Buy, Sell, or Hold?

Kenvue (KVUE) faces regulatory and reputational challenges from the Trump administration's claims linking acetaminophen to autism. Despite a strong defense from CEO Kirk Perry, the company's stock has fallen 20% in 2025. The board has made decisive leadership changes, including Perry's appointment, to address operational struggles and external pressure. KVUE's strong brand equity and gross margins provide reasons for cautious optimism, but investors should be aware of potential market share erosion and litigation risks.

Kenvue Inc. (KVUE) has been grappling with significant regulatory and reputational challenges following recent claims by the Trump administration linking acetaminophen to autism. The company's stock has fallen by 20% in 2025, a substantial decline that has raised concerns among investors.

The allegations, which were reported by the Wall Street Journal, suggest that federal health officials plan to warn pregnant women against using acetaminophen, the active ingredient in Tylenol, early or unless they have a fever. Additionally, the administration intends to promote Leucovorin as a potential autism treatment Kenvue Shares Drop Ahead Of Trump’s ‘Biggest Announcement’ On Autism: Reports Say Administration To Link Tylenol With Risk Of Disease^[2].

Despite the strong defense from CEO Kirk Perry, who has been appointed to address operational struggles and external pressure, the company's stock has continued to fall. The appointment of Perry and other decisive leadership changes by the board aim to bolster the company's operational efficiency and navigate the external pressure effectively.

Kenvue's financial performance remains robust, with a gross margin of 58% and an EBIT margin of 16%. These strong financial metrics provide reasons for cautious optimism. However, investors should be aware of potential market share erosion and litigation risks stemming from the ongoing regulatory scrutiny and reputational damage.

The company's strong brand equity and gross margins are encouraging signs, but the impact of the allegations on consumer confidence and market share remains uncertain. Kenvue must navigate these challenges with strategic counteractions and transparent engagement with both the market and stakeholders to restore investor faith.

As the company continues to face these challenges, the financial sea remains dynamic. While some suggest strategic retreats, others spot opportunities in the wake of potential rebounds. Kenvue's ability to traverse these obstacles will ultimately depend on earnest maneuvers and transparent engagement with both the market and stakeholders.